Ramona Godbole
Research Subjects
Ramona Godbole has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Catherine Nichols
1 shared publicationFrank Tanser
1 shared publication- Jonas Wachinger
Heidelberg Institute of Global Health (HIGH), Heidelberg University
1 shared publication Marissa Courey
1 shared publicationRose Mpembeni
1 shared publication- Shannon A. McMahon
Heidelberg Institute of Global Health (HIGH), Heidelberg University
1 shared publication
Latest Publications
- Open Access
- 24 June 2026
- Published by Springer Nature in Nature Health
- Vol. 1 (11) , 1193-1199
Shifts in PEPFAR-supported HIV treatment in 26 countries from 2024 to 2025
Here we analysed recently released treatment data from the US President’s Emergency Plan for AIDS Relief (PEPFAR) programme following a year of disruption. Globally ( n = 55 countries), the programme reported approximately 1.97 million (−10.2%) fewer individuals receiving PEPFAR-supported antiretroviral treatment in fiscal year (FY) 2025 as compared with FY2024. FY2025 treatment budget execution declined by approximately 8 percentage points compared with the historical mean. Within a subset of countries selected for further analysis ( n = 26), most experienced absolute declines in PEPFAR-supported treatment and 14 deviated negatively from pre-2025 trends. For South Africa, PEPFAR reported a decline of ∼1.73 million individuals on direct PEPFAR-supported treatment and an increase of ∼1.64 million individuals on treatment benefitting solely from the programme’s broader support to health systems, yielding a net treatment loss of 94,881 (−1.8%) individuals. Outstanding questions remain regarding the drivers, persistence and broader impact of PEPFAR-supported treatment shifts, underscoring the need for timely programme data.
- 24 June 2026
- Published by Springer Nature in Nature Health
- Vol. 1 (11) , 1193-1199
Open AccessShifts in PEPFAR-supported HIV treatment in 26 countries from 2024 to 2025
Here we analysed recently released treatment data from the US President’s Emergency Plan for AIDS Relief (PEPFAR) programme following a year of disruption. Globally ( n = 55 countries), the programme reported approximately 1.97 million (−10.2%) fewer individuals receiving PEPFAR-supported antiretroviral treatment in fiscal year (FY) 2025 as compared with FY2024. FY2025 treatment budget execution declined by approximately 8 percentage points compared with the historical mean. Within a subset of countries selected for further analysis ( n = 26), most experienced absolute declines in PEPFAR-supported treatment and 14 deviated negatively from pre-2025 trends. For South Africa, PEPFAR reported a decline of ∼1.73 million individuals on direct PEPFAR-supported treatment and an increase of ∼1.64 million individuals on treatment benefitting solely from the programme’s broader support to health systems, yielding a net treatment loss of 94,881 (−1.8%) individuals. Outstanding questions remain regarding the drivers, persistence and broader impact of PEPFAR-supported treatment shifts, underscoring the need for timely programme data.